Form 4: Zymeworks Director Receives Equity Awards

Zymeworks Inc. director Susan Mahony was granted 11,500 stock options and 7,700 restricted stock units, vesting in January 2027.

Summary

• Susan Mahony, a Director of Zymeworks Inc. (ZYME), acquired 11,500 stock options and 7,700 restricted stock units (RSUs) on January 12, 2026.
• The stock options have an exercise price of $23.16 per share and will vest on January 12, 2027, with an expiration date of January 11, 2036.
• Each RSU represents the contingent right to receive one share of common stock upon vesting.
• The RSUs will vest on January 12, 2027.
• Both transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, which is a positive for aligning management interests with shareholders but does not indicate a significant operational or financial event.

Positives

• The equity grants align the director's financial interests with the long-term performance and shareholder value of Zymeworks Inc.
• The use of a Rule 10b5-1(c) plan demonstrates a commitment to transparent and pre-planned insider trading practices.

Negatives

• The awards do not represent immediate cash compensation and their value is contingent on future stock performance and vesting conditions.
• The exercise price of the stock options ($23.16) means the stock must trade above this price for the options to have intrinsic value at exercise.

Risks

• The value of the stock options and RSUs is subject to market volatility and the overall performance of Zymeworks Inc.'s common stock.
• Failure to meet vesting conditions (e.g., continued service) would result in forfeiture of the awards.

Future Outlook

The equity grants are designed to incentivize the director's long-term commitment and contribution to Zymeworks Inc.'s future success, with vesting contingent on continued service through January 2027.

Industry Context

The grant of equity awards to directors is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages to attract and retain talent while aligning leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a common compensation practice in the biotechnology and pharmaceutical industries, aiming to align the interests of board members with long-term shareholder value.
• This structure is comparable to compensation packages observed at peer companies within the sector, which often include a mix of cash and equity incentives to foster long-term commitment and performance.

Corporate Governance

Related Party Transactions

• Grant of equity awards (11,500 stock options and 7,700 restricted stock units) to Susan Mahony, a director of Zymeworks Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value, potentially leading to more focused decision-making for company growth.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options and restricted stock units are scheduled to vest on January 12, 2027, contingent on the director's continued service.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for a director, which is a standard practice and does not provide new material information to warrant a change in investment recommendation. It reflects ongoing corporate governance and compensation practices.

Keywords

Zymeworks, ZYME, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, RSU, Equity Grant, Director Compensation, 10b5-1 Plan, Biotechnology